Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Esophageal squamous cell carcinoma (ESCC) is a globally lethal malignancy requiring novel therapeutic strategies.
• The mevalonate (MVA) pathway, crucial for cholesterol and isoprenoid synthesis, has not been previously explored in ESCC.
• Identifying new therapeutic targets is critical for improving outcomes in ESCC patients.

Purpose of the Study:

• To investigate the role of the MVA pathway in ESCC.
• To evaluate the therapeutic potential of statins, MVA pathway inhibitors, against ESCC.
• To elucidate the molecular mechanisms underlying statin's effects in ESCC.

Main Methods:

• Analysis of MVA pathway components in ESCC clinical samples.
• In vitro cytotoxicity assays of statin on ESCC and non-tumorigenic cells.
• Assessment of statin's effects on cell apoptosis, cell cycle, and xenograft tumor growth in vivo.
• Molecular analysis of signaling pathways, including ERK, PCNA, Cyclin D1, and PARP cleavage.

Main Results:

• The MVA pathway was found to be upregulated in ESCC tissues.
• Statins exhibited significant cytotoxicity against ESCC cells, inhibiting proliferation and inducing apoptosis and cell cycle arrest.
• Statin treatment effectively suppressed xenograft tumor growth in a dose-dependent manner.
• Molecular analyses revealed statin's impact on ERK activation and key cell cycle/apoptosis markers.

Conclusions:

• The MVA pathway plays a significant role in ESCC progression by influencing cell growth and proliferation.
• Statins demonstrate considerable potential as therapeutic agents for esophageal squamous cell carcinoma.
• Targeting the MVA pathway represents a promising strategy for ESCC treatment.